These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 30253242

  • 1. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
    Liao G, Yang D, Ma L, Li W, Hu L, Zeng L, Wu P, Duan L, Liu Z.
    Eur J Med Chem; 2018 Nov 05; 159():1-9. PubMed ID: 30253242
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
    Gonzalez AZ, Li Z, Beck HP, Canon J, Chen A, Chow D, Duquette J, Eksterowicz J, Fox BM, Fu J, Huang X, Houze J, Jin L, Li Y, Ling Y, Lo MC, Long AM, McGee LR, McIntosh J, Oliner JD, Osgood T, Rew Y, Saiki AY, Shaffer P, Wortman S, Yakowec P, Yan X, Ye Q, Yu D, Zhao X, Zhou J, Olson SH, Sun D, Medina JC.
    J Med Chem; 2014 Apr 10; 57(7):2963-88. PubMed ID: 24601644
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C, McDonnell JM.
    Future Med Chem; 2009 Sep 10; 1(6):1075-94. PubMed ID: 21425995
    [Abstract] [Full Text] [Related]

  • 9. MDM2 inhibition: an important step forward in cancer therapy.
    Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, Ott M, Mascarenhas J, Andreeff M.
    Leukemia; 2020 Nov 10; 34(11):2858-2874. PubMed ID: 32651541
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer.
    Rew Y, Sun D.
    J Med Chem; 2014 Aug 14; 57(15):6332-41. PubMed ID: 24967612
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Small molecule inhibitors of the p53-MDM2.
    Hu CQ, Hu YZ.
    Curr Med Chem; 2008 Aug 14; 15(17):1720-30. PubMed ID: 18673221
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T, Oishi S, Honda K, Kondoh Y, Saito T, Kubo T, Kaneda M, Ohno H, Osada H, Fujii N.
    Bioorg Med Chem Lett; 2013 Jul 01; 23(13):3802-5. PubMed ID: 23726030
    [Abstract] [Full Text] [Related]

  • 18. Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives.
    Fang Y, Liao G, Yu B.
    Acta Pharm Sin B; 2020 Jul 01; 10(7):1253-1278. PubMed ID: 32874827
    [Abstract] [Full Text] [Related]

  • 19. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C, Carotti A, Magnani M, Baroni M, Padova A, Cruciani G, Macchiarulo A, Pellicciari R.
    J Chem Inf Model; 2010 Aug 23; 50(8):1451-65. PubMed ID: 20726601
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.